0.5448
Precedente Chiudi:
$0.5858
Aprire:
$0.5858
Volume 24 ore:
969.08K
Relative Volume:
0.09
Capitalizzazione di mercato:
$26.98M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-2.12%
1M Prestazione:
+49.42%
6M Prestazione:
-34.04%
1 anno Prestazione:
+0.00%
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Nome
Aspire Biopharma Holdings Inc
Settore
Industria
Telefono
561-704-8527
Indirizzo
194 CANDELARO DRIVE, #233, HUMACAO
Confronta ASBP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ASBP
Aspire Biopharma Holdings Inc
|
0.5448 | 28.50M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Borsa (ASBP) Ultime notizie
Aspire Biopharma Reports Final Results in Sublingual Aspirin Trial for Heart Attack Treatment; Shares Fall Pre Bell - MarketScreener
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - ACCESS Newswire
2-Minute Response Time: Aspire's New Sublingual Aspirin Could Revolutionize Heart Attack Treatment - Stock Titan
How to track smart money flows in Banc of California Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Weekly Investment Recap & Fast Moving Market Watchlists - Newser
How to track smart money flows in aTyr Pharma Inc.2025 Price Targets & Free Real-Time Volume Trigger Notifications - Newser
ExlService Holdings Inc. stock chart pattern explainedTrade Exit Summary & Free Safe Entry Trade Signal Reports - Newser
Combining price and volume data for Shell plc Depositary ReceiptEarnings Risk Summary & Technical Buy Zone Confirmation - Newser
Aspire Biopharma Secures $9.7M Through Securities Agreement - MSN
How to track smart money flows in TTEC Holdings Inc.2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser
Historical volatility pattern of Zoomcar Holdings Inc. visualizedJuly 2025 Trends & Precise Swing Trade Entry Alerts - Newser
What earnings revisions data tells us about Newton Golf Company Inc.July 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
Risk vs reward if holding onto Edesa Biotech Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - Newser
What MACD and RSI say about CHSNWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser
Aspire Biopharma enters $9.7 million note purchase agreement with investors By Investing.com - Investing.com Nigeria
Aspire Biopharma's Debt Refinancing: A Strategic Play for Biotech Capital Structure Optimization and Operational Flexibility - AInvest
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Promising Penny Stocks To Consider – August 18th - Defense World
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On?Aspire Biopharma Hldgs (NASDAQ:ASBP) - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Miami Herald
Aspire Biopharma to Present at Sidoti Virtual Investor Conference - AInvest
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
New Pre-Workout BUZZ BOMB Hits Market With Instant-Acting Sublingual Technology - Stock Titan
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Lubbock Avalanche-Journal
Riding the Waves: A Guide to Investing in ASBP Stock - investchronicle.com
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
Aspire Biopharma Holdings Inc Azioni (ASBP) Dati Finanziari
Non sono disponibili dati finanziari per Aspire Biopharma Holdings Inc (ASBP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):